ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Ro 08-2750 increases radiation-induced cytotoxicity in DLBCL by dysregulating the DNA damage response.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
purposeCurrent research aims to increase treatment efficacy in diffuse large B‑cell lymphoma (DLBCL). Recently, Musashi‑2 (MSI-2) was identified as a negative prognostic marker and potential therapeutic target in DLBCL. Here, we evaluated the effect of the MSI‑2 inhibitor Ro 08-2750 in DLBCL cells.
methodsFirst, we established the effects of Ro 08-2750 on DLBCL in cell viability and clonogenicity assays. Changes in cell cycle and apoptosis were analyzed flow cytometrically. We then evaluated modifications in DLBCL treatment response when combining radiation treatment or chemotherapy with Ro 08-2750. Following confirmation of a Ro 08-2750-associated increase in radiation-induced DNA damage via a γH2AX assay, an immunoblot-based assay was used to detect changes in radiation-induced DNA damage repair protein activation. To understand Ro 08-2750-induced modifications in gene expression and protein abundance, we performed RT-qPCR, bulk mRNA-sequencing, western blotting, and quantitative mass spectrometry-based proteomic analyses.
resultsRo 08-2750 reduced cell viability and proliferation in DLBCL. Functionally, Ro 08-2750 induced cell cycle arrest in the S phase, where the DNA synthesis rate was attenuated. Additionally, apoptosis was increased. Ro 08-2750 also sensitized DLBCL cell lines to irradiation but not to chemotherapy, and it increased irradiation-induced DNA double-strand breaks. Transcriptome and proteome analyses showed changes in various tumor-associated signaling pathways, primarily associating Ro 08-2750 with compromised DNA repair, cell cycle, and cell division.
conclusionWe identified Ro 08-2750 as a radiosensitizer in DLBCL. Our results suggest that the combination of Ro 08-2750 with radiation therapy may enhance treatment efficacy.
Indexed as
Identifiers
42467206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.